Transplantation outcome
. | No. patients affected/no. evaluable patients (%) . | . | |
|---|---|---|---|
| Parameter . | HLA-identical . | HLA-nonidentical . | |
| Early deaths, before day 21 | 5/62 (8) | 1/25 (4) | |
| Sustained engraftment | 56/57 (99) | 22/25 (88) | |
| GVHD | |||
| Acute, grades II-IV | 40/57 (70) | 18/24 (75) | |
| Chronic* | 25/48 (52) | 12/21 (57) | |
| Overall survival | 38/62 (61) | 11/25 (44) | |
| Survival by regimen | |||
| CY + ATG + TBI | |||
| –3 × 200 cGy | 4/8 (50) | 2/6 (33) | |
| –2 × 200 cGy | 6/12 (50) | 3/6 (50) | |
| –1 × 200 cGy | 23/35 (66) | 5/11 (45) | |
| CY + TBI (6 × 200) | 5/7 (71) | 0/2 (0) | |
. | No. patients affected/no. evaluable patients (%) . | . | |
|---|---|---|---|
| Parameter . | HLA-identical . | HLA-nonidentical . | |
| Early deaths, before day 21 | 5/62 (8) | 1/25 (4) | |
| Sustained engraftment | 56/57 (99) | 22/25 (88) | |
| GVHD | |||
| Acute, grades II-IV | 40/57 (70) | 18/24 (75) | |
| Chronic* | 25/48 (52) | 12/21 (57) | |
| Overall survival | 38/62 (61) | 11/25 (44) | |
| Survival by regimen | |||
| CY + ATG + TBI | |||
| –3 × 200 cGy | 4/8 (50) | 2/6 (33) | |
| –2 × 200 cGy | 6/12 (50) | 3/6 (50) | |
| –1 × 200 cGy | 23/35 (66) | 5/11 (45) | |
| CY + TBI (6 × 200) | 5/7 (71) | 0/2 (0) | |
Median follow-up was 7 years (range, 1.2-10.2 years)
Chronic GVHD requiring therapy